Purpose: The purpose of this study was to compare the volume of fluid removal associated with and without 25% albumin administration in conjunction with hemodialysis. Methods: This retrospective, cohort study was conducted at a large academic medical center over a 6-month period to compare the net fluid amount removed (mL) during hemodialysis between patients administered 25% albumin and those without albumin. Results: A total of 238 patients consisting of 973 unique hemodialysis sessions were evaluated. The mean overall net fluid removed by hemodialysis in the 25% albumin and no albumin groups were 1242 mL and 1899 mL, P < .001, respectively. No albumin group had significantly higher mean fluid losses compared with 25% albumin for a total dose of either 25 g (P = .001) or 50 g (P = .001). There were no significant differences in mean fluid loss between the no albumin group and patients receiving 75 g or 100 g of albumin. Post hoc analysis failed to demonstrate a dose-dependent response in those patients receiving 25% albumin and no albumin. Conclusion: Hyperoncotic albumin administered during hemodialysis sessions reduced net fluid loss associated with hemodialysis. The findings of this study do not support the routine use of 25% albumin to improve fluid removal during dialysis.
Purpose: The purpose of this study was to compare the volume of fluid removal associated with and without 25% albumin administration in conjunction with hemodialysis. Methods: This retrospective, cohort study was conducted at a large academic medical center over a 6-month period to compare the net fluid amount removed (mL) during hemodialysis between patients administered 25% albumin and those without albumin. Results: A total of 238 patients consisting of 973 unique hemodialysis sessions were evaluated. The mean overall net fluid removed by hemodialysis in the 25% albumin and no albumin groups were 1242 mL and 1899 mL, P < .001, respectively. No albumin group had significantly higher mean fluid losses compared with 25% albumin for a total dose of either 25 g (P = .001) or 50 g (P = .001). There were no significant differences in mean fluid loss between the no albumin group and patients receiving 75 g or 100 g of albumin. Post hoc analysis failed to demonstrate a dose-dependent response in those patients receiving 25% albumin and no albumin. Conclusion: Hyperoncotic albumin administered during hemodialysis sessions reduced net fluid loss associated with hemodialysis. The findings of this study do not support the routine use of 25% albumin to improve fluid removal during dialysis.
Authors: Frank M VAN DER Sande; Antinus J Luik; Jeroen P Kooman; Vic Verstappen; Karel M L Leunissen Journal: J Am Soc Nephrol Date: 2000-03 Impact factor: 10.121
Authors: Jose I Suarez; Renee H Martin; Samuel F Hohmann; Eusebia Calvillo; Eric M Bershad; Chethan P Venkatasubba Rao; Alexandros Georgiadis; Oliver Flower; David Zygun; Simon Finfer Journal: Crit Care Med Date: 2017-01 Impact factor: 7.598
Authors: Peter F Lyu; Jason M Hockenberry; Laura M Gaydos; David H Howard; Timothy G Buchman; David J Murphy Journal: Crit Care Med Date: 2016-07 Impact factor: 7.598
Authors: Nicole Hryciw; Michael Joannidis; Swapnil Hiremath; Jeannie Callum; Edward G Clark Journal: Clin J Am Soc Nephrol Date: 2020-10-28 Impact factor: 8.237